ABOUT US
Scientific Advisory Board

Timothy Springer Scholar Rock
For more information:
Springer Lab
Leonard Zon Scholar Rock
For more information:
Zon Lab
Barry Coller Scholar Rock
For more information:
Coller Lab
Scott Friedman Scholar Rock
For more information:
Friedman Lab
Michael Gilman Scholar Rock
Dr. Gilman is a scientist, general manager, biotech executive, and serial entrepreneur. He is currently Chair and CEO for Arrakis Therapeutics and CEO and Director for Obsidian Therapeutics. He also serves on the Board of Directors of X4 Pharmaceuticals and the SAB of FutuRx, an Israeli biotech accelerator. Previously, Dr. Gilman was Founder and CEO of Padlock Therapeutics, a venture-funded company focused on autoimmune disease, acquired by Bristol-Myers Squibb in 2016. Prior to Padlock, Dr. Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec, with responsibility for managing the company’s development programs through clinical proof-of-concept. He joined Biogen Idec in March 2012 following its acquisition of Stromedix, a venture-backed company focused on fibrosis and organ failure, where he was Founder and CEO. Prior to founding Stromedix in 2006, Dr. Gilman served as EVP, Research at Biogen Idec, with responsibility for the company’s discovery research activities in Cambridge and San Diego. From 1994 to 1999, Dr. Gilman was at ARIAD Pharmaceuticals, where he was EVP and CSO. From 1986 to 1994, Dr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Dr. Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and a S.B. in Life Sciences from Massachusetts Institute of Technology.
Joan Massague Scholar Rock
For more information:
Massagué Lab
Daniel Rifkin Scholar Rock
For more information:
Rifkin Lab
Lynn Sakai Scholar Rock
For more information:
Sakai Lab
Lynn Sakai Scholar Rock
Dr. Vaishnaw joined Alnylam in 2006, coming from Biogen, Inc. (now Biogen Idec Inc.), where he was most recently Senior Director, Translational Medicine. In his seven years at Biogen he was involved in many aspects of clinical research and business development, and led the effort for the approval of alefacept (Amevive™) for psoriasis. Akshay received his M.D. from the University of Wales College of Medicine, U.K., with Distinctions in Pathology and Medicine, and his Ph.D. from the University of London, U.K., in Molecular Immunology. He is a Member of the Royal College of Physicians, U.K. In addition, Akshay has published papers in leading scientific journals and authored a number of textbook chapters relating to autoimmune disease.
Shelia Violette Scholar Rock
Dr. Violette was previously Vice President of Tissue Injury and Fibrosis Research at Biogen where she spearheaded a team of scientists conducting discovery research and developing translational approaches to advance programs into clinical development. From 2008 to 2012, Dr. Violette was Vice President of Research at Stromedix and led all research activities supporting the development of the anti-v6 antibody, STX-100. Dr. Violette has more than 20 years of industry experience advancing programs from early research to clinical development. She has provided strategic and operational leadership to multi-disciplinary teams of scientists and authored more than 80 manuscripts and patents. Dr. Violette has directed research and led therapeutic programs at several biotechnology companies including Repligen, Ariad, Stromedix and Biogen. She is currently an Entrepreneur in Residence at Atlas Venture, Cambridge, MA. Dr. Violette received her Ph.D. in Pharmacology from Yale University and carried out her post-doctoral training with Frank Ruddle in the Department of Biology at Yale University.